{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(5)"],"submitter":["Mediani L"],"pubmed_abstract":["PEL is a B-cell non-Hodgkin lymphoma, occurring predominantly as a lymphomatous effusion in body cavities, characterized by aggressive clinical course, with no standard therapy. Based on previous reports that PEL cells display a Warburg phenotype, we hypothesized that the highly hypoxic environment in which they grow in vivo makes them more reliant on glycolysis, and more vulnerable to drugs targeting this pathway. We established here that indeed PEL cells in hypoxia are more sensitive to glycolysis inhibition. Furthermore, since PI3K/Akt/mTOR has been proposed as a drug target in PEL, we ascertained that pathway-specific inhibitors, namely the dual PI3K and mTOR inhibitor, PF-04691502, and the Akt inhibitor, Akti 1/2, display improved cytotoxicity to PEL cells in hypoxic conditions. Unexp"],"journal":["Oncotarget"],"pagination":["5521-37"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4868703"],"repository":["biostudies-literature"],"pubmed_title":["Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling."],"pmcid":["PMC4868703"],"pubmed_authors":["Rampazzo E","Mattiolo A","Cocco L","Calabro ML","Riva G","Capitani S","Frasson C","Petrizza L","Potenza L","Bosco R","Bonora M","Sgarbi G","Milani D","Baracca A","Luppi M","De Pol A","Pinton P","Accordi B","Gibellini F","Prodi L","Mediani L","Bertacchini J","Marmiroli S","Basso G"],"additional_accession":[]},"is_claimable":false,"name":"Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.","description":"PEL is a B-cell non-Hodgkin lymphoma, occurring predominantly as a lymphomatous effusion in body cavities, characterized by aggressive clinical course, with no standard therapy. Based on previous reports that PEL cells display a Warburg phenotype, we hypothesized that the highly hypoxic environment in which they grow in vivo makes them more reliant on glycolysis, and more vulnerable to drugs targeting this pathway. We established here that indeed PEL cells in hypoxia are more sensitive to glycolysis inhibition. Furthermore, since PI3K/Akt/mTOR has been proposed as a drug target in PEL, we ascertained that pathway-specific inhibitors, namely the dual PI3K and mTOR inhibitor, PF-04691502, and the Akt inhibitor, Akti 1/2, display improved cytotoxicity to PEL cells in hypoxic conditions. Unexp","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2026-05-29T20:22:16.449Z","creation":"2026-04-08T06:02:36.733Z"},"accession":"S-EPMC4868703","cross_references":{"pubmed":["26575168"],"doi":["10.18632/oncotarget.6315"]}}